TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors - PubMed (original) (raw)
Clinical Trial
. 2009 Jul 30;114(5):1099-109.
doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7.
Brit B Turnbull, Kartoosh Heydari, Judith A Shizuru, Ginna G Laport, David B Miklos, Laura J Johnston, Sally Arai, Wen-Kai Weng, Richard T Hoppe, Philip W Lavori, Karl G Blume, Robert S Negrin, Samuel Strober, Robert Lowsky
Affiliations
- PMID: 19423725
- PMCID: PMC2721787
- DOI: 10.1182/blood-2009-03-211441
Clinical Trial
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Holbrook E Kohrt et al. Blood. 2009.
Abstract
A hematopoietic cell transplantation regimen was adapted from a preclinical model that used reduced-intensity conditioning (RIC) and protected against graft-versus-host disease (GVHD) by skewing residual host T-cell subsets to favor regulatory natural killer T cells. One hundred eleven patients with lymphoid (64) and myeloid (47) malignancies received RIC using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) followed by the infusion of granulocyte colony-stimulating factor-mobilized grafts. Included were 34 patients at least 60 years of age, 32 patients at high risk of lymphoma relapse after disease recurrence following prior autologous transplantation, and 51 patients at high risk of developing GVHD due to lack of a fully human leukocyte antigen (HLA)-matched related donor. Durable chimerism was achieved in 97% of patients. Cumulative probabilities of acute GVHD (grades II-IV) were 2 and 10% of patients receiving related and unrelated donor grafts. Nonrelapse mortality (NRM) at 1 year was less than 4%. Cumulative incidence of chronic GVHD was 27%. The 36-month probability of overall and event-free survival was 60% and 40%, respectively. Disease status at start of conditioning and the level of chimerism achieved after transplantation significantly impacted clinical outcome. The high incidence of sustained remission among patients with active disease at time of transplantation suggests retained graft-versus-tumor reactions. Active trial registration currently at clinicaltrials.gov under IDs of NCT00185640 and NCT00186615.
Figures
Figure 1
Effect of TLI + ATG on circulating T-cell subsets. Absolute T-cell subset population size pre-TLI (x-axis) and immediately post-TLI (y-axis) with plotted linear regression (solid lines, constrained through 0,0) for CD3, CD4, CD8, and NKT-cell subsets. Dashed line representative of a population with no change (y = x) in population size between pre-TLI and immediately post-TLI (A). Boxplot of fold decrease in CD3, CD4, CD8, and NKT-cell populations (median, thick line; quartiles, box; range, whiskers; outliers, circle; B).
Figure 2
NRM. Cumulative incidence of NRM, with 95% CIs, among patients who received matched-related donor (A) and matched-unrelated donor (B) grafts with competing risks of relapse.
Figure 3
GVHD. Cumulative incidence of acute GVHD with 95% CIs, among patients who received matched-related donor (A) and matched-unrelated donor (B) grafts. Cumulative incidence of chronic GVHD with 95% CIs, among patients who received matched-related donor (C) and matched-unrelated donor (D) grafts. Cumulative incidence of acute and chronic GVHD were calculated with competing risks including relapse, death, and primary graft failure.
Figure 4
Effect of disease status at transplant on OS and EFS. Kaplan-Meier OS (A) and EFS (B) curve estimates among patients with NHL stratified by disease status at time of transplantation (first CR, PR, or SD and PD). Kaplan-Meier OS (C) and EFS (D) curve estimates among patients with de novo AML stratified by disease status at time of transplantation (first CR, second CR, or beyond second remission including persistent disease). Corresponding 36-month OS or EFS noted. The OS curve for patients with de novo AML falls below the EFS at 19.5 months as an artifact of censoring of 2 subjects between the times of another subject's relapse and death.
Figure 5
Effect of chimerism on OS and EFS. Kaplan-Meier OS (A) and EFS (B) curve estimates among patients with NHL enrolled with CR or PR stratified by chimerism (complete or mixed chimerism, no graft failures occurred). Kaplan-Meier OS (C) and EFS (D) curve estimates among patients with de novo AML enrolled with disease control, CR1 or CR2 stratified by chimerism (complete, mixed, or primary graft failure). Corresponding 36-month OS or EFS noted.
Similar articles
- Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. Spinner MA, et al. Blood Adv. 2019 Aug 27;3(16):2454-2464. doi: 10.1182/bloodadvances.2019000297. Blood Adv. 2019. PMID: 31427277 Free PMC article. - Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN. Lee KH, et al. Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25. Biol Blood Marrow Transplant. 2017. PMID: 28552421 Clinical Trial. - Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Hamadani M, et al. Biol Blood Marrow Transplant. 2009 Nov;15(11):1422-30. doi: 10.1016/j.bbmt.2009.07.006. Epub 2009 Sep 1. Biol Blood Marrow Transplant. 2009. PMID: 19822302 Free PMC article. Clinical Trial. - Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
Cited by
- Traversing the bench to bedside journey for iNKT cell therapies.
O'Neal J, Mavers M, Jayasinghe RG, DiPersio JF. O'Neal J, et al. Front Immunol. 2024 Aug 7;15:1436968. doi: 10.3389/fimmu.2024.1436968. eCollection 2024. Front Immunol. 2024. PMID: 39170618 Free PMC article. Review. - Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice.
Sligar C, Reilly E, Cuthbertson P, Vine KL, Bird KM, Elhage A, Alexander SI, Sluyter R, Watson D. Sligar C, et al. Clin Transl Immunology. 2024 Mar 15;13(3):e1497. doi: 10.1002/cti2.1497. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38495918 Free PMC article. - Maintain Efficacy and Spare Toxicity: Traditional and New Radiation-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation.
Dogliotti I, Levis M, Martin A, Bartoncini S, Felicetti F, Cavallin C, Maffini E, Cerrano M, Bruno B, Ricardi U, Giaccone L. Dogliotti I, et al. Cancers (Basel). 2024 Feb 21;16(5):865. doi: 10.3390/cancers16050865. Cancers (Basel). 2024. PMID: 38473227 Free PMC article. Review. - Graft-versus-Host Disease Modulation by Innate T Cells.
Fang Y, Zhu Y, Kramer A, Chen Y, Li YR, Yang L. Fang Y, et al. Int J Mol Sci. 2023 Feb 17;24(4):4084. doi: 10.3390/ijms24044084. Int J Mol Sci. 2023. PMID: 36835495 Free PMC article. Review. - Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.
Courtney AN, Tian G, Metelitsa LS. Courtney AN, et al. Blood. 2023 Feb 23;141(8):869-876. doi: 10.1182/blood.2022016201. Blood. 2023. PMID: 36347021 Free PMC article. Review.
References
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400. - PubMed
- Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24:444–453. - PubMed
- Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–3542. - PubMed
- Georges GE, Maris M, Sandmaier BM, et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol. 2002;76(suppl 1):184–189. - PubMed
- Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–1629. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA049605/CA/NCI NIH HHS/United States
- P01 HL075462/HL/NHLBI NIH HHS/United States
- P30 CA124435/CA/NCI NIH HHS/United States
- 1P030CA124435-01/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials